Drug intelligence / Profile preview

BH0688

Development stage: Preclinical
Lead developer: Beijing Hanmei Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BH0688 is a bispecific antibody currently in the discovery stage, developed by Beijing Hanmei Pharmaceutical. It is designed to target Lymphocyte-activation gene 3 (LAG3) and an undisclosed second target for the treatment of various tumors. LAG3 is an immune checkpoint receptor that negatively regulates T-cell activation and proliferation; by blocking LAG3, BH0688 aims to restore anti-tumor immune responses. The inclusion of a second, undisclosed target suggests a synergistic mechanism of action, likely involving another immune checkpoint or a tumor-associated antigen, to enhance therapeutic efficacy in oncology.

Targets

LAG3 (Lymphocyte activation Gene-3 protein)

Beyond the preview

Go deeper on BH0688.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH0688.

Explore the full profile